Novel azelnidipine crystal form, preparation method for same and officinal composition thereof

The invention provides a novel azelnidipine crystal form, a preparation method for the same and an officinal composition thereof. The X-ray powder diffraction characteristic absorption peak value 2theta of the novel azelnidipine crystal form is 5.68, 11.33, 12.34, 13.18, 13.55, 15.00, 16.26, 18.16, 20.60, 21.50, 23.09, 23.66, 24.62 and 27.19. The preparation method for the novel azelnidipine crystal form includes the steps: mixing amorphous azelnidipine with methylbenzene according to amount ratio ranging from 1:4 to 1:6 (w/v) prior to heating, adding activated carbon with stirring and filtering, adding cyclohexane into filtrate with the amount ratio of the cyclohexane to the methylbenzene ranging from 1:2 to 2:1 (v/v), and obtaining the novel azelnidipine crystal form by means of crystallization, filtration and drying. The novel azelnidipine crystal form is durable in drug properties, small in static electricity, higher in stability, high in yield and suitable for mass production.